Literature DB >> 20308387

Plasmodium vivax susceptibility to ferroquine.

M L Leimanis1, A Jaidee, K Sriprawat, S Kaewpongsri, R Suwanarusk, M Barends, A P Phyo, B Russell, L Renia, F Nosten.   

Abstract

The novel organometallic chloroquine analog ferroquine (SSR 97193) is effective against chloroquine-resistant Plasmodium falciparum. The ex vivo efficacy of ferroquine against Plasmodium vivax isolates was tested. Ferroquine has a potent ex vivo effect on P. vivax schizont maturation (median 50% inhibitory concentration, 15 nM; n = 42). No significant cross-sensitivity between ferroquine and other antimalarials was detected. This drug may be a suitable replacement for chloroquine in the treatment of drug-resistant P. vivax malaria.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308387      PMCID： PMC2863649          DOI： 10.1128/AAC.01572-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds.

Authors:  C Biot; L Delhaes; C M N'Diaye; L A Maciejewski; D Camus; D Dive; J S Brocard
Journal:  Bioorg Med Chem       Date:  1999-12       Impact factor: 3.641

2.  In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum.

Authors:  Wassim Daher; Lydie Pelinski; Sylvie Klieber; Freddy Sadoun; Viviane Meunier; Martine Bourrié; Christophe Biot; François Guillou; Gérard Fabre; Jacques Brocard; Laurent Fraisse; Jean-Pierre Maffrand; Jamal Khalife; Daniel Dive
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

3.  In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum.

Authors:  Andrea Kreidenweiss; Peter G Kremsner; Klaus Dietz; Benjamin Mordmüller
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

Review 4.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Effects of chloroquine upon the maturation of asexual erythrocytic forms of Plasmodium vivax in vitro.

Authors:  R D Powell; E M Berglund
Journal:  Am J Trop Med Hyg       Date:  1974-11       Impact factor: 2.345

6.  Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.

Authors:  Jason D Maguire; Hariyani Marwoto; Thomas L Richie; David J Fryauff; J Kevin Baird
Journal:  Clin Infect Dis       Date:  2006-03-13       Impact factor: 9.079

7.  Improved assessment of plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay.

Authors:  Pierre Druilhe; Philippe Brasseur; Catherine Blanc; Michael Makler
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

8.  In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon.

Authors:  Christiane Atteke; Jérôme Mezui Me Ndong; Agnès Aubouy; Lucien Maciejewski; Jacques Brocard; Jacques Lébibi; Philippe Deloron
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

9.  Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; M Wuwung; A Brockman; M D Edstein; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-10-09       Impact factor: 2.184

10.  Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure.

Authors:  Wassim Daher; Christophe Biot; Thierry Fandeur; Helene Jouin; Lydie Pelinski; Eric Viscogliosi; Laurent Fraisse; Bruno Pradines; Jacques Brocard; Jamal Khalife; Daniel Dive
Journal:  Malar J       Date:  2006-02-07       Impact factor: 2.979
View more
  7 in total

1.  Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.

Authors:  Fredrick L Eyase; Hoseah M Akala; Jacob D Johnson; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.

Authors:  S Kaewpongsri; K Sriprawat; R Suwanarusk; D E Kyle; U Lek-Uthai; M Leimanis; K M Lwin; A P Phyo; J Zwang; B Russell; F Nosten; L Renia
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; Barbara Machunter; Emiliana Tjitra; Nicholas M Anstey; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

Review 4.  The antimalarial ferroquine: from bench to clinic.

Authors:  C Biot; F Nosten; L Fraisse; D Ter-Minassian; J Khalife; D Dive
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

Review 5.  Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.

Authors:  Arezoo Rafiee Parhizgar; Azar Tahghighi
Journal:  Iran J Med Sci       Date:  2017-03

Review 6.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

7.  Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity.

Authors:  B Russell; B Malleret; R Suwanarusk; C Anthony; S Kanlaya; Y L Lau; C J Woodrow; F Nosten; L Renia
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.